Delanzomib(CEP-18770)|cas 847499-27-8|DC Chemicals

Cas No.:	847499-27-8
Chemical Name:	((R)-1-((2S,3R)-3-Hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutyl)boronic acid
Synonyms:	((R)-1-((2S,3R)-3-Hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutyl)boronic acid;CEP-18770 (Delanzomib);[(1R)-3-Methyl-1-({N-[(6-phenyl-2-pyridinyl)carbonyl]-L-threonyl} amino)butyl]boronic acid;CEP18770;CEP-18770;Delanzomib;Delanzomib(CEP18770)
SMILES:	CC(C)C[C@@H](B(O)O)NC([C@@H](NC(C1=NC(C2=CC=CC=C2)=CC=C1)=O)[C@H](O)C)=O
Formula:	C₂₁H₂₈BN₃O₅
M.Wt:	413.27512
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Delanzomib(CEP-18770) is a novel orally-active inhibitor of the chymotrypsin-like activity of the proteasome that down-modulates the nuclear factor-kappaB (NF-kappaB) activity.

Cat. No.	Product name	Field of application
DC2010	Oprozomib (ONX-0912)	Oprozomib (ONX 0912) selectively inhibits CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.
DC5089	Ixazomib Citrate (MLN-9708)	MLN-9708 is a proteasome inhibitor, which inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome.
DC8481	Delanzomib(CEP-18770)	Delanzomib(CEP-18770) is a novel orally-active inhibitor of the chymotrypsin-like activity of the proteasome that down-modulates the nuclear factor-kappaB (NF-kappaB) activity.
DC1002	Carfilzomib (PR-171)	Carfilzomib is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells,showed potent activity against COVID-19(SARS-COV-2).
DC1027	Bortezomib (Velcade,MG-341,PS-341)	Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM.